Understanding blood vessel diseases and inflammation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the interrelation between thrombotic, immune, and vascular diseases, focusing on how these conditions develop and evolve over time. Participants, including those affected by these diseases, their healthy relatives, and unrelated healthy volunteers, will undergo a baseline visit involving medical history, physical exams, and optional blood tests. The study seeks to collect data and biospecimens to inform future clinical investigations and improve understanding of vascular health. By examining clinical, radiographic, immunological, and genetic characteristics, researchers hope to develop better diagnostic and management strategies.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Age \>= 5 years at the time of consent
* Ability of subject or Legally Authorized Representative (LAR) as applicable to understand and the willingness to sign a written informed consent document

In addition, the following cohort-specific inclusion criteria apply:

Affected Subjects:

-Known or possible thrombotic, immune, or vascular disorder after review of the subject s medical records and/or discussion of medical history

Relatives of Affected Subjects:

-Being a relative of an affected subject

Unrelated Healthy Controls:

-In good general health as evidenced by medical history

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

-Any condition that in the opinion of the Investigator would warrant exclusion

Unrelated Healthy Controls:

* Unrelated healthy volunteers who decline to have blood drawn and/or tissue studies or who do not consent to have samples stored for future research
* Cognitively impaired individuals

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Yogendra Kanthi, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Jessenia C Campos, R.N.
• Email: jessenia.campos@nih.gov
• Phone: (301) 402-0300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

• Coronary CT angiography–guided calcium modification during PCI for calcified coronary artery disease

  This study will see if using CT angiography to plan calcium treatment before stenting helps people with flow-limiting, calcified coronary artery disease have better stent results and faster procedures compared with the usual ultrasound-guided PCI while keeping similar safety.

  Recruiting at 10 sites Fundación EPIC · Boston, Massachusetts and 14 other locations · NCT07286578

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• RADIANCE CED: long-term outcomes after ultrasound renal denervation

  This project will see if ultrasound renal denervation (using the Paradise system) lowers blood pressure over the long term in Medicare-age adults (65+) with uncontrolled hypertension by using their medical records.

  Recruiting at 2 sites ReCor Medical, Inc. · Detroit, Michigan and 1 other locations · NCT07231757

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.